Thank you for participating!

Thank you to all who contributed to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. Ultimately, over 1,000 ideas were submitted, with more than 42,000 votes. This remarkable response exceeded expectations and provided a wealth of ideas to draw upon as NHLBI moves forward. Please visit the NHLBI Strategic Visioning page to find out more about the NHLBI Strategic Visioning process.


Welcome to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. The Institute is gathering ideas for the most compelling scientific priorities in the four NHLBI Strategic Goals to address over the next decade.

Goal 2: Reduce Human Disease

Can we safely move CAR therapy i beyond limited academic centers?

CAR therapy has resurrected the role of immunotherapy in treating cancer. But it has significant toxicity. Can we train , standardize the care of and adequately oversee the care of patients getting CAR therapy , especially as company begin to approach FDA for approval of this therapy and up scale for mass treatment.

Submitted by (@lholmber)

Voting

11 net votes
26 up votes
15 down votes
Active

Goal 3: Advance Translational Research

Personalized Medicine thru CV bioinformation/tissue repository

There is a need to establish virtual CV biologic tissues and a bioinformational repository for specific CV diseases, including congenital cardiovascular malformations, genetic or other unique cardiomyopathies, such as stress cardiomyopathy and giant cell myocarditis.

Submitted by (@nhlbiforumadministrator1)

Voting

-13 net votes
10 up votes
23 down votes
Active

Goal 2: Reduce Human Disease

Rare Diseases

A study section should be seated for clinical trials on rare disease. Members of this study section should consist only of individuals who have previously performed phase I and/or phase II trials, developed IND or IDE applications, or who have extensive experience in informatic or biometric support for clinical trials. My opinion is that seating individuals on these sections who have a laboratory career in cellular or ...more »

Submitted by (@nhlbiforumadministrator)

Voting

2 net votes
2 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

Study on key product factors for optimal Bone Marrow Transplantation (BMT) graft function

Hematopoietic progenitor cells (HPC) collected by Apheresis is the most common source used for BMT. How the cells are collected and what kinds of cells are collected can affect BMT graft function. Limited studies have been done to study the key product factors in relationship to optimal graft function. Questions remain such as the optimal lymphocytes contents for reduced infection post BMT, optimal megakaryocyte precursor ...more »

Submitted by (@yanyunw)

Voting

70 net votes
93 up votes
23 down votes
Active

Goal 2: Reduce Human Disease

Optimize vaccine responses in HCT recipients and patients with hematologic malignancies

Vaccination responses are poor early after hematopoietic cell transplantation and in the context of cytotoxic chemotherapy. To design effective vaccination strategies it is critical to understand the immune correlates of protection. There is a need to study strategies to study and improve vaccine efficacy in this growing population of immunosuppressed individuals that is increasingly of advanced age.

Submitted by (@mboeckh)

Voting

15 net votes
25 up votes
10 down votes
Active

Goal 2: Reduce Human Disease

Consequences of drug interactions leading to QTc prolongation

Better understand the consequences of drug interactions leading to QTc prolongation. About 1/3 of cardiac ICU patients develop QT prolongation and about 45% receive drugs that are possibly contributing to this problem. The full spectrum of contributors and causes, as well as the patient-centered and health-system-centered clinical outcomes, are not known.

Submitted by (@greg.martin)

Voting

-1 net votes
1 up votes
2 down votes
Active

Goal 3: Advance Translational Research

Development of Novel Apheresis Adsorption Technologies to More Effectively and Safely Treat Hematologic Diseases

Current FDA approved apheresis technology currently uses elutriation/centrifugation separation techniques to remove pathologic cellular and/or plasma elements. These techniques are non-specific, limited by inefficient removal kinetics and often require considerable blood product exposure. Despite tremendous improvement in our understanding of the pathophysiology of a variety of disease, our ability to treat many of ...more »

Submitted by (@ewong0)

Voting

93 net votes
112 up votes
19 down votes
Active

Goal 3: Advance Translational Research

Molecular determinants of vascular wall development and aneurysm formation that can be used as markers for early diagnosis

To increase the potential of translating basic research discoveries into the clinic, there is a need to discover molecular biomarkers that confer risk for aneurysms and vascular dissections. The creation of a nation-wide biorepository of well-defined tissue and plasma samples along with research utilizing these tissue samples employing state-of-the art proteomics, genomics and development of appropriate mouse models will ...more »

Submitted by (@dstrickland)

Voting

5 net votes
7 up votes
2 down votes
Active

Goal 4: Develop Workforce and Resources

Promotion of interdisciplinary science to address therapeutic challenges in cardiac arrhythmias management

The main therapeutic challenges that remain to be addressed in the field of cardiac arrhythmias generally require the participation of scientific expertises as diverse as physiology, medicine, engineering, chemistry, nanotechnology, material science and others. Today, there is little incentive to assemble such cross-expertise teams. Novel funding mechanisms could reward the time and effort invested in forming cross-expertise ...more »

Submitted by (@jeromekalifa)

Voting

-10 net votes
7 up votes
17 down votes
Active